Cargando…

Performance of NI-RADS on CECT Alone to Predict Recurrent Head and Neck Squamous Cell Carcinoma after Chemoradiotherapy: Added Value of RECIST 1.1.

Background The Head and Neck Imaging Reporting and Data System (NI-RADS) is a standardized reporting format for the categorization of the degree of suspicion for recurrent head and neck malignancies on positron emission tomography/computed tomography. Purpose The purpose of our study was to analyz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Ishan, Reza, Syed O., Choudhary, Sunil, Shukla, Ram C., Mani, Nilesh, Verma, Ashish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340179/ https://www.ncbi.nlm.nih.gov/pubmed/35924129 http://dx.doi.org/10.1055/s-0042-1754315

Ejemplares similares

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC
por: Wen, Rong, et al.
Publicado: (2023)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
por: Iannessi, Antoine, et al.
Publicado: (2021)

iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020)

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents
por: Le Tourneau, C, et al.
Publicado: (2012)

Congenital thyroid hemiagenesis with thyroid nodules—Role of TI-RADS to prevent long term thyroid replacement therapy
por: Verma, Ashish, et al.
Publicado: (2016)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
por: Xu, Ying, et al.
Publicado: (2022)

RECIST Applied to Realistic Tumor Models
por: Levine, Zachary H., et al.
Publicado: (2011)

Imaging tumour response: beyond RECIST
por: Koh, Dow-Mu
Publicado: (2014)

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yu, Hongli, et al.
Publicado: (2022)

Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
por: Zheng, Bingjie, et al.
Publicado: (2021)

Precontrast T1 signal measurements of normal pituitary and microadenoma: A retrospective analysis through DCE MRI signal time curves
por: Kumar, Ishan, et al.
Publicado: (2018)

Utility of Contrast-Enhanced Ultrasound in Differentiation between Benign Mural Lesions and Adenocarcinoma of Gallbladder
por: Kumar, Ishan, et al.
Publicado: (2019)

Magnetic resonance neurographic confirmation of extensive Plexiform neurofibroma in neurofibromatosis-1 presenting as ambiguous genitalia
por: Kumar, Ishan, et al.
Publicado: (2016)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

A Letter in Support of Real-World RECIST
por: Gajra, Ajeet, et al.
Publicado: (2020)

Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT
por: Matoba, Munetaka, et al.
Publicado: (2015)

Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
por: Beaumont, Hubert, et al.
Publicado: (2023)

Bacillus amyloliquefaciens CECT 5940 alone or in combination with antibiotic growth promoters improves performance in broilers under enteric pathogen challenge
por: de Oliveira, Marllon José Karpeggiane, et al.
Publicado: (2019)

Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer
por: Imano, Nobuki, et al.
Publicado: (2020)

Utility of magnetic resonance imaging in the diagnosis of unsuspected cases of Parsonage-Turner syndrome: two case reports
por: Kumar, Ishan, et al.
Publicado: (2013)

A Combination of Lactoplantibacillus plantarum Strains CECT7527, CECT7528, and CECT7529 Plus Monacolin K Reduces Blood Cholesterol: Results from a Randomized, Double-Blind, Placebo-Controlled Study
por: Guerrero-Bonmatty, Rafael, et al.
Publicado: (2021)

Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: case report
por: Naghashzadeh, Farah, et al.
Publicado: (2022)

Imaging beyond RECIST: CT and MRI in molecular therapies
por: Diederich, Stefan
Publicado: (2012)

Response assessment in daily practice: RECIST and its modifications
por: Sohaib, Aslam
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a37ocfkfbrga0u68s9i2s0117l